A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.
U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk of hospitalization, U.S. officials said.
Shares of Prevail Therapeutics skyrocketed in trading after Eli Lilly announced the acquisition of the gene therapy company in a deal valued at $1.04 billion.
The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.
U.S. hospitals, weighing high demand and tight supplies, said they may limit use of the new Eli Lilly and Co. nantibody drug bamlanivimab to Covid-19 patients with multiple risk factors for serious illness or to those whose immune systems have not begun to fight the infection.
Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.
U.S. Health Secretary Alex Azar said if pharmaceutical company Pfizer Inc. submits interim Covid-19 vaccine to health regulators as quickly as expected, the U.S. government anticipates the beginning of vaccinating Americans in December.
Regeneron Pharmaceuticals Inc.’s coronavirus antibody cocktail – the experimental treatment that U.S. President Donald Trump received – significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate Covid-19.